journal
MENU ▼
Read by QxMD icon Read
search

Clinical and Applied Thrombosis/hemostasis

journal
https://www.readbyqxmd.com/read/29514466/postthrombotic-syndrome-in-patients-treated-with-rivaroxaban-or-warfarin-for-venous-thromboembolism
#1
Craig I Coleman, Jan Beyer-Westendorf, Thomas J Bunz, Charles E Mahan, Alex C Spyropoulos
Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism (VTE). Using MarketScan claims data from January 2012 to June 2015, we identified adults with a primary diagnosis code for VTE during a hospitalization/emergency department visit, ≥6 months of insurance coverage prior to the index event and newly started on rivaroxaban or warfarin within 30 days of the index VTE. Patients with <4-month follow-up postindex event or a claim for any anticoagulant during 6-month baseline period were excluded...
May 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29363999/all-cause-stroke-systemic-embolism-and-major-bleeding-related-health-care-costs-among-elderly-patients-with-nonvalvular-atrial-fibrillation-treated-with-oral-anticoagulants
#2
Steve Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Patrick Hlavacek, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
In this study, all-cause, stroke/systemic embolism (SE)-related, and major bleeding (MB)-related health-care costs among elderly patients with nonvalvular atrial fibrillation (NVAF) initiating treatment with different oral anticoagulants (OACs) were compared. Patients ≥65 years of age initiating OACs, including apixaban, rivaroxaban, dabigatran, and warfarin, were identified from the Humana Research Database between January 1, 2013, and September 30, 2015. Propensity score matching was used to separately match the different OAC cohorts with the apixaban cohort...
May 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29363998/comparative-evaluation-of-biological-performance-biosecurity-and-availability-of-cellulose-based-absorbable-hemostats
#3
Yadong Wu, Fang Wang, Yudong Huang
Hemorrhage remains a leading cause of death after trauma, and developing a hemostat with excellent performance and good biosecurity is an extremely active area of research and commercial product development. Although oxidized regenerated cellulose (ORC) has been developed to address these problems, it is not always efficient and its biosecurity is not perfect. We aimed to refine ORC via a simple and mild neutralization method. The prepared neutralized oxidized regenerated cellulose (NORC) showed a superior gel property due to its chemical structure...
May 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29277101/incidence-and-management-of-thrombotic-and-thromboembolic-complications-following-the-superior-cavopulmonary-anastomosis-procedure-a-literature-review
#4
Arnav Agarwal, Mohammed Firdouse, Nishaan Brar, Andy Yang, Panos Lambiris, Anthony K Chan, Tapas Kumar Mondal
The objective of this literature review was to estimate the incidence of thrombosis and thromboembolism associated with the superior cavopulmonary anastomosis (SCPA) procedure and its variants and to examine current thromboprophylaxis regimens utilized. MEDLINE and EMBASE were searched from inception to August 2017 for all prospective and retrospective cohort studies explicitly reporting incidence of thrombosis, thromboembolism, or shunt occlusion in neonates, infants, and children undergoing 1 or more variants of the SCPA procedure...
April 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29258392/validation-of-a-patient-completed-caprini-risk-assessment-tool-for-spanish-arabic-and-polish-speakers
#5
Luis H Paz Rios, Harry E Fuentes, Diana M Oramas, Xavier A Andrade, Ahmed Al-Ogaili, Mina Iskander, Fady Iskander, Amir Nagui Abdalla Iskandar, Wictoria Kowacz, Adam Iwanski, Christine Acob, Luis Diaz Quintero, Juan Pablo Salazar-Adum, Alfonso Tafur, Joseph A Caprini
Targeted prophylaxis for venous thromboembolism (VTE) using the Caprini risk score (CRS) is effective reducing postoperative VTE. Despite its availability as preventive strategy, risk scoring remains underutilized. Critics to the CRS contend the time it takes to complete, and its limitation to English language. Aim is to create and validate patient-completed CRS tools for Spanish, Arabic, and Polish speakers. We translated the first patient-completed CRS to Spanish, Arabic, and Polish. We conducted a pilot study followed by the validation study...
April 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28914077/decision-algorithms-for-direct-oral-anticoagulant-use-in-patients-with-nonvalvular-atrial-fibrillation-a-practical-guide-for-neurologists
#6
Isabella Canavero, Giuseppe Micieli, Maurizio Paciaroni
Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings...
April 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29212374/performance-of-anti-factor-xa-versus-activated-partial-thromboplastin-time-for-heparin-monitoring-using-multiple-nomograms
#7
Emily Whitman-Purves, James C Coons, Taylor Miller, Jeannine V DiNella, Andrew Althouse, Mark Schmidhofer, Roy E Smith
The purpose of this study was to compare the performance of anti-factor Xa concentration versus activated partial thromboplastin time (aPTT) monitoring with multiple indication-specific heparin nomograms. This was a prospective, nonrandomized study with historical control at a large academic medical center. A total of 201 patients who received intravenous heparin in the cardiology units were included. The prospective cohort included patients (n = 101) with anti-factor Xa (anti-Xa) monitoring, and the historical control group included patients (n = 100) who had aPTT monitoring...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29179580/association-of-fv-g1691a-polymorphism-but-not-a4070g-with-coronary-artery-disease
#8
Ahmed Amara, Meriem Mrad, Aicha Sayeh, Abdeddayem Haggui, Dhaker Lahideb, Najiba Fekih-Mrissa, Habib Haouala, Brahim Nsiri
Coronary artery disease (CAD) is one of the chief causes of death in the world. Several hypotheses have been promoted as for the origin of the disease, among which are genetic predispositions and/or environmental factors. The aim of this study was to determine the effect of factor V (FV) gene polymorphisms (Leiden, G1691A [FVL] and HR2 A4070G) and to analyze their association with traditional risk factors in assessing the risk of CAD. Our study population included 200 Tunisian patients with symptomatic CAD and a control group of 300 participants matched for age and sex...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29108420/inhibitor-risk-stratification-and-individualized-treatment-in-patients-with-nonsevere-hemophilia-a-a-single-institution-practice-audit
#9
Haowei Linda Sun, Stella Chan, Paul Yenson, Shannon Jackson
Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluated the uptake of these strategies into clinical practice. All adult males with nonsevere hemophilia A followed by British Columbia Adult Hemophilia Program from 2004 to 2016 were included in this retrospective audit...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29050501/platelet-activation-assessed-by-glycoprotein-vi-platelet-ratio-is-associated-with-portal-vein-thrombosis-after-hepatectomy-and-splenectomy-in-patients-with-liver-cirrhosis
#10
Toshiki Matsui, Masanobu Usui, Hideo Wada, Yusuke Iizawa, Hiroyuki Kato, Akihiro Tanemura, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno, Hiroyuki Sakurai, Shuji Isaji
Portal vein thrombosis (PVT) is a serious complication after hepatobiliary-pancreatic surgery. Portal vein thrombosis often develops in patients with liver cirrhosis (LC) postoperatively, although they have low platelet counts. Platelet activation is one of the causes of thrombosis formation, and soluble form of glycoprotein VI (sGPVI) has received attention as a platelet activation marker. We had prospectively enrolled the 81 consecutive patients who underwent splenectomy (Sx) and/or hepatectomy: these patients were divided as Sx (n = 38) and hepatectomy (Hx, n = 46) groups...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28990414/biomarkers-of-endothelial-renal-and-platelet-dysfunction-in-stage-5-chronic-kidney-disease-hemodialysis-patients-with-heart-failure
#11
Ryan McMillan, Leonidas Skiadopoulos, Debra Hoppensteadt, Nil Guler, Vinod Bansal, Ravipresenna Parasuraman, Jawed Fareed
The aim of this study was to determine the role of endothelial, renal, and inflammatory biomarkers in the pathogenesis of heart failure (HF) in patients with stage 5 chronic kidney disease (CKD5) undergoing maintenance hemodialysis (HD). Plasma levels of biomarkers-kidney injury molecule 1 (KIM-1), N-terminal pro brain natriuretic peptide (NT-proBNP), glycated hemoglobin, neutrophil gelatinase-associated lipocalin, interleukin-18,platelet-derived growth factor, platelet factor 4 (PF4), 25-OH vitamin D, parathyroid hormone (PTH), endothelin, and endocan-were measured in CKD5-HD patients at the Loyola University Ambulatory Dialysis facility...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28774195/description-and-evaluation-of-the-implementation-of-a-weight-based-nurse-driven-heparin-nomogram-in-a-tertiary-academic-medical-center
#12
James W Schurr, Craig A Stevens, Anne Bane, Carol Luppi, Sarah E Culbreth, Amy Leigh Miller, Jean M Connors, Katelyn W Sylvester
Weight-based, nurse-driven heparin nomograms are reported in the medical literature to improve the time it takes to reach a minimum threshold for anticoagulation without compromising patient safety in specific indications or patient populations. This is the first report in the literature of an institution-wide protocol implementation and evaluation of effectiveness with simultaneous transition to an electronic health record. The purpose of implementing this practice change at our institution was to standardize practice, improve time to reach therapeutic anticoagulation, and improve patient safety...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28731369/experimental-evaluation-of-tranexamic-acid-loaded-porous-starch-as-a-hemostatic-powder
#13
Chaoyun Xi, Liguo Zhu, Yuan Zhuang, Shufang Wang, Guixiang Sun, Yaqian Liu, Deqing Wang
We evaluated the effectiveness of a novel hemostatic powder called Tranexamic Acid-loaded Porous Starch (TAPS) developed recently on blood clotting activity and hemostasis. The effectiveness of TAPS was evaluated by comparing hemostatic properties with those of Quick-acting Styptic Powder (QSP) and Compound Microporous Polysaccharide Haemostatic powder (CMPHP). The blood clotting activities of human blood were analyzed by thromboela-stogram (TEG) assays in vitro. The hemostatic effectiveness in vivo was evaluated using a rat model with hepatic traumatic hemorrhage...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28718296/real-life-management-of-venous-thromboembolism-with-rivaroxaban-results-from-experience-vte-an-italian-epidemiological-survey
#14
Davide Imberti, Giovanni Barillari
Two large randomized controlled trials examined the efficacy and safety of rivaroxaban for the treatment of venous thromboembolism (VTE). The aim of this epidemiological study was to analyze a cohort of Italian patients affected by VTE who were treated with rivaroxaban in clinical practice. The data were collected by physicians using an online electronic questionnaire. The study was performed during a 6-month period from January to June 2014. We analyzed the clinical characteristics, risk factors for VTE, comorbidities, diagnostic techniques, and treatments in the whole population and in the subgroups with deep vein thrombosis (DVT) only, pulmonary embolism (PE) only, and DVT+PE...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28703014/thrombin-receptor-agonist-peptide-induced-platelet-aggregation-is-reduced-in-patients-receiving-dabigatran
#15
Frantisek Nehaj, Juraj Sokol, Michal Mokan, Jela Ivankova, Maros Mokan
The availability of direct oral anticoagulants has caused a paradigm shift in thrombosis management. The direct thrombin inhibitor dabigatran seems to obstruct tenase complex by inhibiting thrombin generated in the initial phase and feed back to the amplification phase of cell-based coagulation reactions. However, it is still not fully understood if and how dabigatran impact platelet function. This observational study aimed to assess in vitro platelet function in patients with atrial fibrillation receiving dabigatran...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28627231/a-novel-risk-scoring-system-to-predict-cardiovascular-death-in-patients-with-acute-myocardial-infarction-cha-2-ds-2-vasc-cf-score
#16
Harun Kundi, Emrullah Kiziltunc, Ahmet Korkmaz, Gokhan Cicek, Ender Ornek, Mehmet Ileri
The present study aimed to determine the long-term prognostic validity of the CHA2 DS2 -VASc score in patients with acute myocardial infarction (AMI). In addition, we formulated a novel scoring system, the CHA2 DS2 -VASc-CF (which includes cigarette smoking and a family history of coronary artery disease as risk factors). This study included 4373 consecutive patients with AMI who presented to the emergency department of our hospital and underwent cardiac catheterization procedures between December 2009 and September 2016...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28511552/r147w-in-proc-gene-is-a-risk-factor-of-thromboembolism-in-thai-children
#17
Nongnuch Sirachainan, Ampaiwan Chuansumrit, Werasak Sasanakul, Najwa Yudhasompop, Lalita Mahaklan, Jarin Vaewpanich, Pimlak Charoenkwan, Somjai Kanjanapongkul, Anannit Visudtibhan, Pakawan Wongwerawattanakoon
The p.R147W mutation, the c.C6152T in exon 7, causing a change in amino acid from arginine to tryptophan of the PROC gene has been reported as a common mutation in Taiwanese populations with venous thromboembolism (VTE). The present study aimed to identify the prevalence of p.R147W in the Thai population and children with TE and the risk of developing TE. Patients aged ≤18 years diagnosed with TE were enrolled. The PROC gene was amplified by polymerase chain reaction using a specific primer in exon 7. The restriction fragment length polymorphism was designed using MwoI restriction enzyme...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28401801/thrombophilia-in-153-patients-with-premature-cardiovascular-disease-%C3%A2-age-45
#18
Alexander Milgrom, Kevin Lee, Matan Rothschild, Frini Makadia, Greg Duhon, Sarah Min, Ping Wang, Charles J Glueck
We assessed contributions of thrombophilia to premature cardiovascular disease (CVD) events (≤ age 45) in 153 patients. Test results of thrombophilia-hypofibrinolysis were obtained in 153 patients with CVD ≤ age 45, 110 healthy normal controls, and 110 patients who had venous thromboembolism (VTE) without CVD. Of the 153 patients with CVD, 121 (79%) had sustained myocardial infarction, 70 (46%) had coronary artery stenting, and 53 (35%) had coronary artery bypass grafts. The first CVD events occurred at ages >20 to 35 in 47 patients and at ages >35 to 45 in 106 patients...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28320219/monitoring-of-argatroban-and-lepirudin-what-is-the-input-of-laboratory-values-in-real-life
#19
Holger Seidel, Hans-Jürgen Kolde
Monitoring of direct thrombin inhibitors (DTIs) in patients with heparin-induced thrombocytopenia (HIT) is primarily performed using the activated partial thromboplastin time (aPTT). This assay is poorly standardized, reagent dependent, and not DTI specific. We compared aPTT, thrombin time (TT), and prothrombin time (PT) to drug levels obtained by the ecarin chromogenic assay (ECA). We analyzed 495 samples of patients with confirmed or suspected HIT on treatment with either argatroban (n = 37) or lepirudin (n = 80)...
March 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28301915/emerging-role-of-direct-oral-anticoagulants-in-the-management-of-heparin-induced-thrombocytopenia
#20
Phu Ngoc Tran, Minh-Ha Tran
Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITT) are rare but potentially limb- and life-threatening complications of heparin therapy. Continuation of heparin or low-molecular-weight heparin is contraindicated due to platelet activation in the presence of (heparin-dependent) HIT antibodies. Primary treatment options currently include argatroban, fondaparinux, or bivalirudin. However, the parenteral administration routes and interference of argatroban with traditional coagulation markers complicate management...
March 2018: Clinical and Applied Thrombosis/hemostasis
journal
journal
32273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"